Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/28431065http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28431065http://www.w3.org/2000/01/rdf-schema#comment"

Aims

Paroxysmal atrial fibrillation (PAF) is often asymptomatic but nonetheless harmful. We evaluated the performance of disease-related blood biomarkers and CHA2DS2-VASc score to discriminate for PAF in patients with continuous rhythm monitoring.

Methods and results

Clinical data and blood samples were obtained from patients with dual-chamber pacemakers selected according to the absence (no_AHRE) or presence of Atrial High-Rate Episodes (AHRE) >6 min in recent device history (case-control approach). We included 93 patients (n = 49 AHRE, n = 44 no_AHRE). In a subgroup with high AHRE burden and confirmed PAF 15 biomarkers were evaluated (n = 19 AHRE-AF vs. n = 20 no_AHRE). Significantly regulated biomarkers were then tested in all patients to distinguish no_AHRE from AHRE (receiver operating characteristics analysis). Hsp27, TGFβ1, cystatin C, matrix metalloproteinases MMP-2,-3,-9, albumin, and serum uric acid were not altered in the subgroup. Tissue inhibitors of metalloproteinases (TIMP) -1,-2,-4; NT-proANP, NT-proBNP, IL-6 and serum amyloid protein A were significantly different in AHRE vs. no_AHRE (subgroup and whole cohort), with best discriminatory performance for TIMP-4. Biomarkers performed better than CHADS2-VASc for AHRE discrimination. Intracardial electrograms and medical history from seven AHRE patients suggested atrial tachycardia and not AF (AHRE-AT). Four of the most relevant regulated biomarkers (TIMP-4, TIMP-2, SAA, NT-proBNP) behaved similarly in AHRE-AT and AHRE-AF. NT-proBNP >150 pg/mL indicated an odds ratio of 12.9 for AHRE. Combining two biomarkers significantly improved discrimination of AHRE.

Conclusion

TIMP-4, NT-proANP, NT-proBNP were strongest associated with PAF and AHRE. The discriminatory performance of CHADS2-VASc for PAF was increased by addition of selected biomarkers."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.org/dc/terms/identifier"doi:10.1093/europace/euw101"xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Neumann B."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Scharnagl H."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Pieske B."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Stojakovic T."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Heinzel F.R."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Wakula P."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Scherr D."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Manninger M."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Kapl M."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Kienemund J."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/author"Thon-Gutschi E."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/name"Europace"xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/pages"544-551"xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/title"CHA2DS2-VASc score and blood biomarkers to identify patients with atrial high-rate episodes and paroxysmal atrial fibrillation."xsd:string
http://purl.uniprot.org/citations/28431065http://purl.uniprot.org/core/volume"19"xsd:string
http://purl.uniprot.org/citations/28431065http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28431065
http://purl.uniprot.org/citations/28431065http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28431065
http://purl.uniprot.org/uniprot/#_B0ZBE8-mappedCitation-28431065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28431065
http://purl.uniprot.org/uniprot/#_P01160-mappedCitation-28431065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28431065
http://purl.uniprot.org/uniprot/#_Q99727-mappedCitation-28431065http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28431065
http://purl.uniprot.org/uniprot/Q99727http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/28431065
▶